Skip to playerSkip to main content
  • 2 months ago
Lipfendra, also known as enlicitide, is a newly approved oral medication for cholesterol management, presenting an alternative to injectable PCSK9 inhibitors for adults struggling with elevated LDL cholesterol levels. The FDA has sanctioned this drug for use as a standalone treatment or in conjunction with statins. Results from two clinical trials involving over 3,000 participants demonstrated LDL reductions of 56% and 59% in comparison to a placebo. Lipfendra is specifically indicated for adults with high LDL cholesterol or those with heterozygous familial hypercholesterolemia. Merck has announced that a monthly supply will be priced at $315 prior to insurance coverage. Ongoing studies are set to explore the drug's potential in reducing cardiovascular incidents and mortality.
Disclosure:This video contains stock footage and content created or enhanced using Ai-assisted tools ai-generated

Category

🗞
News
Transcript
00:00A new FDA-approved pill could give some patients another way to lower high cholesterol.
00:05The drug, called Lipfendra, is the first oral form of a PCSK9 inhibitor.
00:10It works differently from statins by helping the liver remove more LDL, or buy it cholesterol.
00:16The medication can be taken alone or alongside statins, depending on the patient.
00:22Two clinical trials included more than 3,000 adults already taking statins.
00:26In one trial, Lipfendra lowered LDL cholesterol by an average of 56% more than placebo.
00:32In another trial involving people with inherited high cholesterol, the reduction reached 59%.
00:38The drug is approved for adults with high LDL cholesterol or familial hypercholesterolemia.
00:45Merck says a 30-day supply will cost $350 before insurance coverage.
00:49Researchers are still studying whether Lipfendra can also reduce heart attacks, strokes, and deaths.
00:55Disclosure.
00:56This video contains stock footage and content created or enhanced, using AI-assisted tools AI generated.

Recommended